CClinicalTrials.gg
Status unknownNCT05402189Updated Jun 2, 2022

Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioids in Cleft Palate Repaire

A Phase 1 interventional study of Ketodex, Fentanyl in Ketodex Versus Opioids Based Anaesthesia in Cleft Palate Repair, sponsored by Ain Shams University. Status unknown at 1 site in Egypt. Open to participants aged 6 Months to 5 Years. Per ClinicalTrials.gov, last updated 2022-06-02.

Sponsored by Ain Shams University · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2022), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2022, registered May 2022).
Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
6 Months to 5 Years
Sex
All
01

Study summary

This study will be conducted to compare Ketodex versus opioid based anaesthesia in cleft palate repair surgeries .

Read the detailed description

According to patients' randomized groups, study medication is given at induction and continues intraoperative not more than 2hours.[8]. Induction of anaesthesia with inhalational anaesthetic will be done through a face mask and Ayres T piece (sevoflurane )8%on 100% oxygen and fresh gas flow of at least double patient minute volume and IV line will be inserted and secured in place .After confirmation of intermittent positive pressure ventilation , 1.5 mg/kg IV suxamethonium will injected. The child will be intubated with an appropriate sized tube, and a throat pack will be placed. Ventilation will be performed with a standard ventilator equipped with a paediatric circle circuit (Datex Ohmeda, Helsinki, Finland), tidal volume of 6-8 ml/kg, and a rate adjusted to maintain the ETCO2 concentration between 32 and 35 mmHg at a total gas flow of 2 L/min. General anaesthesia will be maintained with 50% O2 + 50% air with atracurium and isoflurane, which will be titrated according to the hemodynamic parameters. Dexamethasone (0.2 mg/kg) will be given as an antiemetic and to reduce airway oedema. Post-intubation, Group (KD) will receive 1mg/kg IV ketamine and 1 µg/kg dexmiditomidine IV diluted in 20 ml NS as a loading dose over 10 min followed by a maintenance infusion of ketamine at 0.1 mg/kg/hr and dexmiditomidine 0.2 µg/kg/hr. IV diluted in 20 ml NS till the end of surgery.(15-16-17) Group (OP) will receive fentanyl 2ug /kg IV diluted in 20 ml NS and another loading syringe containing 20 ml normal saline as a loading dose over 10 min followed by a maintenance infusion of another 20 ml syringes, one containing fentanyl and the other containing normal saline . Maintenance dose of fentanyl in this group will be 0.5 µg /kg/hr . Pre-operative fasting fluid deficits and intraoperative losses will be replaced with crystalloid. A single shot of intravenous antibiotic will be given. At the end of surgery, patients will be reversed with 0.05mg/kg IV neostigmine and 0.02 mg/kg atropine, and extubated after meeting the standard extubation criteria

02

Conditions studied

  • Ketodex Versus Opioids Based Anaesthesia in Cleft Palate Repair

Browse trials for

Keywords

  • Ketodex, opioids, cleft palate
03

In context

Cleft Palate

131 studies on the registry are indexed under Cleft Palate; 36 are open to participants now.

This study's planned enrollment of 50 is above the median of 40 across 85 interventional studies indexed under Cleft Palate.

Browse Cleft Palate studies →

Lead sponsor

Ain Shams University is the lead sponsor of 1,876 studies on the registry; 423 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age 6 months to 5 years; both sex, American Society of anaesthesiologists' physical status I or II; no associated any other congenital anomalies.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of prematurity delayed motor , mental or developmental milestones, long QT syndrome, are excluded from the study allergy to study drugs
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Ketodex group : Group (KD)

    Drug: Ketodex, Fentanyl

  • Active comparator
    Opioid group: Group (OP)

    Drug: Ketodex, Fentanyl

Interventions

  • DrugKetodex, Fentanyl

    The patients will be randomized into 2 groups : group (KD) and group (OP) . Two 20 ml syringes, labelled loading and another two 20 ml syringes labelled maintenance will be given to each patient according to his group. Group (KD): patients will receive 1mg/kg ketamine and 1ug/kg dexmiditomidine in their respective loading syringes diluted in 20ml normal saline. Then , they will receive ketamine 0.1 mg/kg /hr and dexmedetomidine0.2ug/kg/hr in their maintenance syringes prepared in 20 ml normal saline in a concentration of 1mg/ml ketamine and 1ug/ml dexmiditomidine respectively . Group (OP): one of the loading syringes will contain fentanyl in a dose of 2ug/kg diluted in 20 ml normal saline and the other loading syringe will contain normal saline. Then, the patients will receive 0.5ug/kg/hr fentanyl through one of the maintenance syringes while the other syringe contains normal saline.

06

What researchers measure

Primary outcomes

  1. postoperative respiratory depression

    This study will be conducted to compare Ketodex versus opioid based anaesthesia in cleft palate repair surgeries as regard postoperative respiratory depression and the need for oxygen

    Time frame: 4 months after starting the study

07

Study locations

1 of 1 sites recruiting
  • Faculty of Medicine Ain Shams University
    Cairo, Egypt
    • Marwa M Mamdouh, Lecturer · Contact · marwaemam600@gmail.com · 01000205686
    • Mohamed A Noser, Lecturer · Contact · 01025841933
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05402189
Lead sponsor
Ain Shams University
Responsible party
Marwa Emam (Lecturer, Ain Shams University) — Principal investigator
First posted
Jun 2, 2022
Start date
Feb 1, 2022
Primary completion
Jun 10, 2022 (estimated)
Completion
Jun 20, 2022 (estimated)
Last update
Jun 2, 2022

Study contacts

Marwa M Mohamed, Lecturer
Contact
marwaemam600@gmail.com
01000205686
Mohamed A Noser, Lecturer
Contact
01025841934

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion